Today Stories

Powered by Sanofi, a new BioMed X research team will develop a computational platform designed to accelerate drug development. Heidelberg, June 29, 2023. BioMed X, a German independent research institute, announces the start of its first research project in collaboration with Sanofi: “Next Generation Virtual Patient Engine for Clinical Translation of Drug Candidates” (VPE). The end goal of this research project is to develop a versatile computational platform that can predict the efficacy of first- or best-in-class drug candidates in virtual patient populations at unprecedented accuracy, thereby addressing one of the most critical bottlenecks of the pharmaceutical industry today: a 90% failure rate of new drug candidates during clinical development. The new research team will be led by D…

Caidya was honored at the CRO Leadership Awards held in Boston, MA at the end of June for their win in the Overall Capabilities category. The award is a recognition of Caidya’s outstanding global capabilities and the tireless work that the team does daily to fulfill our vision to ensure potential therapies have the best opportunity to reach patients in need. Vice President of Business Development (China), Jinye Shen, attended on behalf of Caidya and expressed her gratitude and excitement for the award in a brief interview with the hosting president, Krishnan Rajugopalan. Key points she raised are: Caidya operates with an ownership mentality towards clinical research, making our clients’ success a measure of our own success. As a global company, we help clients navigate regulatory complexi…

Sanofi, Meningitis Research Foundation, and the Confederation of Meningitis Organisations ignite a global awareness initiative against meningitis with launch of The Meningitis Flag Paris, August 28, 2023. Today, Meningitis Research Foundation, the Confederation of Meningitis Organisations (CoMO) and Sanofi join forces to launch ‘The Meningitis Flag’, a global initiative to raise awareness in the fight against meningitis. With the Paris 2024 Paralympic Games opening in exactly one year, and with the support of para-athletes Ellie Challis (Great Britain), Théo Curin (France), and Davide Morana (Italy), this unique global campaign seeks to increase understanding of a disease that remains one of the world’s largest infectious disease killers, and yet is largely preventable.1,2 Despite major pr…

NEW BRUNSWICK, N.J., August 23, 2023 – Johnson & Johnson (NYSE: JNJ) today announced the final results of its previously announced offer to its shareholders to exchange their shares of Johnson & Johnson common stock for shares of Kenvue Inc. (NYSE: KVUE) (“Kenvue”) common stock owned by Johnson & Johnson. The exchange offer expired at 12:00 midnight, New York City time, at the end of the day on August 18, 2023. Pursuant to the exchange offer, Johnson & Johnson has accepted 190,955,436 shares of Johnson & Johnson common stock in exchange for 1,533,830,450 shares of Kenvue common stock. Because the exchange offer was oversubscribed, Johnson & Johnson accepted only a portion of the shares of its common stock that were validly tendered and not validly withdrawn, on a pr…

PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today published its 2022 Environmental, Social, and Governance (ESG) Report, which details the Company’s goals, strategies, and performance across its four ESG focus areas including ethics, integrity, and quality; health equity and access to healthcare; global inclusion and diversity; and environmental sustainability. As a leading biopharmaceutical company, Bristol Myers Squibb is committed to discovering, developing, and delivering innovative medicines that help patients prevail over serious diseases. The Company’s ESG strategy is embedded in its mission and builds on a legacy of comprehensive and global sustainability efforts that seek to drive business value and positively impact patients, employees, communities, and th…

23 August 2023: Kadans Science Partner (“Kadans”) is set to welcome AviadoBio to its recently completed wet lab innovation and flexible workspace centre at 20 Water Street in Canary Wharf. AviadoBio, a pioneering gene therapy company developing and delivering transformative medicines for neurodegenerative disorders, will establish laboratory and office presence at the Innovation Centre. AviadoBio will begin working at Kadans’ London Innovation Centre following the recent completion of their wet-lab Innovation Centre at levels four and five at 20 Water Street. The company will be joining the Kadans’ growing European ecosystem of over 450 tenants including Cytiva, Akamis Bio, GeneFirst and Sherlock Bioscience. Lisa Deschamps, CEO of AviadoBio, said: “We are very excited about our new partner…

Strategic Partnership Aims to Revolutionize Cancer Screening and Enhance Healthcare Outcomes, Bringing Innovative Genetic Testing Solutions to Individuals Across Poland BERKELEY, US – MAINZ, Germany – August 22, 2023 — Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”) , a molecular genetics diagnostic company specializing in the early detection of cancer, announces the commercial launch of ColoAlert® in Poland, made possible through a strategic collaboration with testDNA Sp. z o. o. Sp. K (“testDNA”). The partnership marks another significant step forward in providing new and innovative testing options to underserved populations in the battle against colorectal cancer (“CRC”). ColoAlert®, Mainz Biomed's flagship product is a user-friendly and highly effective at-home screenin…

Wealth of heart failure data supports medical guideline updates and underscores commitment to improving patient outcomes AstraZeneca will present 19 abstracts, including 10 oral presentations and five late-breaking presentations, at the European Society of Cardiology (ESC) Congress from 25-28 August 2023, which includes data highlighting the opportunities for improved management in heart failure (HF), and AstraZeneca’s leadership across the interconnectedness of chronic diseases. Among these abstracts will be sub-analyses from the DELIVER trial – a trial that has been pivotal in informing updates to medical guidelines. Notably, new late-breaking data from a pooled analysis of DELIVER and DAPA-HF trials assess the efficacy of Forxiga (dapagliflozin) versus placebo in HF patients whose…

AQUIPTA® (atogepant) is the first and only once-daily oral calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) in the European Union (EU) approved for the prophylaxis of migraine in adults who have four or more migraine days per month Approval is based on two pivotal Phase 3 studies that demonstrated statistically significant reduction in mean monthly migraine days with AQUIPTA compared to placebo in adult patients with both chronic and episodic migraine The approval expands AbbVie's portfolio of therapies for adult patients in the EU across migraine frequencies, including episodic and chronic migraine NORTH CHICAGO, Ill., Aug. 17, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the European Commission has approved AQUIPTA® (atogepant) for the prophylaxis of…

– Collaboration Combines Gilead’s Oncology and Inflammation Expertise and Tentarix ’s Tentacles™ Platform – – Gilead Receives Exclusive Rights to Acquire Novel Therapies From this Collaboration – FOSTER CITY, Calif. & SAN DIEGO--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq:GILD) and Tentarix Biotherapeutics today announced that the companies established three multi-year collaborations leveraging Tentarix’s proprietary Tentacles™ platform to discover and develop multi-functional, conditional protein therapeutics for oncology and inflammatory diseases. Designed to enhance both therapeutic benefit and safety, these molecules have the potential to conditionally target immune cells related to disease pathways without activating other immune cells that may create adverse events. “At Gil…

INDIANAPOLIS, Aug. 14, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Sigilon Therapeutics, Inc. (NASDAQ: SGTX). The acquisition allows Lilly to continue researching and developing encapsulated cell therapies, including SIG-002, for the treatment of type 1 diabetes. "Make life better – that's the phrase that guides everything we do at Lilly," said Ruth Gimeno, Ph.D., group vice president, diabetes, obesity and cardiometabolic research at Lilly. "We are excited to welcome our new colleagues from Sigilon to Lilly; together, we will strive to provide solutions for people living with type 1 diabetes that absolves them of constant disease management, and advance Sigilon's technology for patients." The Offer and the Merger A…

INDIANAPOLIS, Aug. 14, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Versanis Bio. The acquisition expands Lilly's portfolio to include Versanis' lead asset, bimagrumab, which is currently being assessed in a Phase 2b study alone and in combination with semaglutide in adults living with overweight or obesity. "Combining our current incretin portfolio, including tirzepatide, with activin receptor blockers such as bimagrumab, could be the next major step in innovative treatments for those living with cardiometabolic diseases, like obesity," said Ruth Gimeno, Ph.D., group vice president, diabetes, obesity and cardiometabolic research at Lilly. "The wealth of knowledge that our new colleagues from Versanis will bring to L…

The two organizations are joining forces to develop pioneering AI-based solutions for efficient chemical synthesis planning to accelerate the development of novel pharmaceuticals. COLUMBUS, Ohio & WARSAW, Poland--(BUSINESS WIRE)--CAS, a division of the American Chemical Society specializing in scientific information solutions, and Molecule.one, a tech-bio leader in AI-based solutions for pharmaceutical chemistry, have established a strategic collaboration focused on the joint development of computer-aided synthesis design technologies to accelerate scientific breakthroughs in early-stage drug discovery and aid chemists in the discovery of novel small molecules. Leveraging their existing technologies and expertise, including Molecule.one’s proprietary generative deep learning models and…

Bagsværd, Denmark and Montreal, Canada, 10 August 2023 – Novo Nordisk A/S and Inversago Pharma today announced that Novo Nordisk has agreed to acquire Inversago for up to 1.075 billion US dollars in cash if certain development and commercial milestones are achieved. Inversago Pharma is a private, Montreal-based developer of CB1 receptor-based therapies for the potential treatment of obesity, diabetes and complications associated with metabolic disorders. The acquisition of Inversago includes the company’s lead development asset INV-202, an oral CB1 inverse agonist. INV-202 is designed to preferentially block the receptor protein CB1 – which plays an important role in metabolism and appetite regulation – in peripheral tissues such as adipose tissues, the gastro-intestinal tract, the kidneys…

INDIANAPOLIS, Aug. 9, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of DICE Therapeutics, Inc. (NASDAQ: DICE). The acquisition expands Lilly's immunology portfolio to include DICE's novel oral therapeutic candidates, including oral IL-17 inhibitors currently in clinical development, to treat chronic diseases in immunology. "Since our founding nearly 150 years ago, we've strived to make life better for people around the world – but we know that to achieve this goal, we have to bring the brightest minds to Lilly," said Ajay Nirula, Ph.D., senior vice president of immunology at Lilly. "With the passion and expertise of our new colleagues from DICE, we look forward to continuing our pursuit of discovering and delivering life…

STORM Therapeutics Ltd. (STORM), a clinical stage biotechnology company focused on discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases, is pleased to announce that it will be presenting the discovery of its lead clinical candidate, STC-15, which is an orally bioavailable and highly selective METTL3 inhibitor, at the American Chemical Society (ACS) Fall 2023 Conference, in San Francisco, California on the 13-17 August 2023. The presentation entitled “Discovery of STC-15, an orally bioavailable, highly selective METTL3 inhibitor for the treatment of AML and solid tumours: The first molecule specifically targeting an RNA methyltransferase enzyme to enter clinical development” will detail the Company’s discovery effor…

Research collaboration leverages bit.bio’s machine learning-powered discovery platform to identify transcription factor (TF) combinations for reprogramming induced pluripotent stem cells (iPSCs) into Tregs. / Agreement includes option for BlueRock to license TF combinations emerging from the collaboration as well as an option to license bit.bio’s opti-oxTM precision cell programming technology for the manufacture and subsequent development of iPSC-derived Treg cell therapies. / bit.bio receives an upfront payment from BlueRock and is eligible to receive milestone payments and royalties on worldwide sales of all therapies resulting from the collaboration. Cambridge, MA USA 7:30 am and Cambridge, UK 12:30pm, August 3, 2023: BlueRock Therapeutics LP, a clinical stage cell t…

Envisioning the future of regulatory and medical writing, CAPTIS Copilot leverages cutting-edge AI models for the Medical Device and Diagnostic industry. CHICAGO--(BUSINESS WIRE)--Celegence, a regulatory compliance service and software solution company, today announced the launch of CAPTIS Copilot, the most advanced document automation and literature review solution for the life sciences industry. CAPTIS Copilot is an enterprise cloud-based platform leveraging pre-trained large language models (LLM) and Reinforcement Learning from Human Feedback (RLHF) for the device and diagnostic industry. This cloud-based solution significantly advances the ability of device and IVD manufacturers to increase innovation and empower clinical, regulatory, and medical writing teams to be more strategic and…

Collaborative Partnership Strengthens Mainz Biomed's Mission to Combat Colorectal Cancer, Saving Lives through Advanced Diagnostics BERKELEY, US – MAINZ, Germany – August 01, 2023 — Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that London-based Marylebone Laboratory (Marylebone Lab Ltd) has introduced ColoAlert®, Mainz Biomed’s flagship product—a highly effective and user-friendly at-home detection test for colorectal cancer (CRC) - to its extensive UK and international customer base. Further strengthening Mainz Biomed’s global network of esteemed laboratory partners, the collaboration marks another significant milestone in the Company’s mission to combat colorectal ca…

– Gilead expands the ALL4LIVER Grant, Providing Grant Funding to Organizations in Africa, South America, Asia and Oceania, Europe and North America  –  Themed ‘Test. Link. Prioritize’, the Grant Program will Target Projects Focusing on Viral Hepatitis Elimination by 2030 –  SINGAPORE, July 28, 2023 – Gilead Sciences, Inc. (Nasdaq: GILD) today announced the launch of the 2023 Gilead ALL4LIVER Grant, a grant program with the theme of ‘Test. Link. Prioritize’, designed to support innovative projects that drive testing, improve linkage to care and/or elevate viral hepatitis on the public health agenda. The ALL4LIVER Grant will support initiatives around the world (excluding the United States) across hepatitis C, hepatitis B or hepatitis D. Eligible organizations can submit funding applications…